Biotechnology US biotech major Celgene Corp (Nasdaq: CELG) said yesterday (July 18) that, after consultation with the US Food and Drug Administration, it will discontinue treatment with Revlimid (lenalidomide) in the open-label, Phase III ORIGIN trial in chronic lymphocytic leukemia, which enrolled 450 patients in over 100 sites in 26 countries. 19 July 2013